Change from baseline in primary and selected secondary end-points with riociguat and placebo in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial (CHEST)-1 study

Primary end-point
 6MWD m88356±75–6±84173342±8239±79<0.001
Selected secondary end-points
 PVR dyn·s·cm–582779±40123±274151791±432–226±248<0.001
 NT-proBNP pg·mL−1731706±256776±14471501508±2338–291±1717<0.001
 WHO-FC87Class I: 0 Class II: 25 (29%) Class III: 60 (69%) Class IV: 2 (2%)13 (15%) moved to lower class; 68 (78%) stayed the same; 6 (7%) moved to higher class173Class I: 3 (2%) Class II: 55 (32%) Class III: 107 (62%) Class IV: 8 (5%)57 (33%) moved to lower class; 107 (62%) stayed the same; 9 (5%) moved to higher class0.003
  • Data are presented as n or mean±sd, unless otherwise stated. 6MWD: 6-min walking distance; PVR: pulmonary vascular resistance; NT-proBNP: N-terminal pro-brain natriuretic peptide; WHO-FC: World Health Organization functional class. #: calculated with the use of stratified Wilcoxon test for the change from baseline to last visit. Reproduced and modified from [26] with permission from the publisher.